Skip Navigation

U.S. Department of Health & Human ServicesLink to HHS.gov
OMH Home

En Español
The Office of Minority Health (Phone: 1-800-444-6472)
About OMH
Our Services
Campaigns/Initiatives
Press Releases
Calendar
Employment
Publications
Federal Clearinghouses
Research
OPHS Home

Image of a person asking a questionNeed Help?
Contact Us
National Partnership for Action to End Health Disparities


Aids.gov - Access to U.S. Government HIV and AIDS information

HIV/AIDS Awareness Days
Join Our Mailing ListJoin Our Mailing List
Click to sign up


OMH Content via HealthDay

  Last Seven Days' Health News
Cimzia Approved for Rheumatoid Arthritis

Previously sanctioned for Crohn's disease

THURSDAY, May 14 (HealthDay News) -- The U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) to treat moderate-to-severe rheumatoid arthritis, Belgian drug maker UCB said Thursday in a news release.

The injected drug was approved in April 2008 to treat the inflammatory bowel disorder Crohn's disease.

Rheumatoid arthritis causes pain, swelling, stiffness and loss of function in the joints, the U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases says. It can affect any joint, but is most common in the wrist and fingers.

Cimzia can have side effects including headache, upper respiratory infection, abdominal pain, nausea and injection site reactions.

More information

The FDA has more about this drug's approval history.

Attribution: -- Scott Roberts
Copyright © 2009 ScoutNews, LLC Exit Disclaimer. All rights reserved.

HealthDayNews articles are derived from various sources and do not reflect federal policy.
omhrc.gov does not endorse opinions, products, or services that may appear in news stories.
Content Last Modified: 5/14/2009 12:51:00 AM
OMH Home  |  HHS Home  |  USA.gov  |  Disclaimer  |  Privacy Policy  |  HHS FOIA  |  Accessibility  |  Site Map  |  Contact Us  |  File Formats

Office of Minority Health
Toll Free: 1-800-444-6472 / Fax: 301-251-2160
Email: info@omhrc.gov

Provide Feedback